Advertisement

Topics

Latest "Insception Biosciences Inc" News Stories

19:05 EDT 22nd September 2018 | BioPortfolio

Here are the most relevant search results for "Insception Biosciences Inc" found in our extensive news archives from over 250 global news sources.

More Information about Insception Biosciences Inc on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Insception Biosciences Inc for you to read. Along with our medical data and news we also list Insception Biosciences Inc Clinical Trials, which are updated daily. BioPortfolio also has a large database of Insception Biosciences Inc Companies for you to search.

Showing "Insception Biosciences" News Articles 1–25 of 1,300+

Saturday 22nd September 2018

Evofem Biosciences Inc EVFM Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12042018] Prices from USD $250

SummaryEvofem Biosciences Inc Evofem formerly known as Neothetics Inc, is a healthcare solution provider that discovers, develops and commercializes prescription and consumer products. The company's product pipeline includes amphora and nestorone. Evofem improves reproductive health and wellness options for women. It develops products for contraception, itching, burning and stinging, fine lines, w...


Friday 21st September 2018

Pace International’s ecoFOG® Receives Sustainability Recognition

Postharvest leader reveals expansion plans for its award winning technology for the 2018-2019 seasons Recognizing its significant contribution to global food waste reduction efforts, Pace International’s ecoFOG® technology has been honored with “Sumika Sustainable Solutions”, status by the company’s parent, Sumitomo Chemical Company (SC...

Roche licenses IPF candidate to Ark Biosciences

Roche’s Genentech Inc. licensed Ark Biosciences Inc. exclusive worldwide development and commercialization rights to its Ph...


DATA: Results Recap: Terumo PulseCath Shows Promise In High-Risk PCI; Reapplix' LeucoPatch Promotes Ulcer-Healing

Results Recap is Medtech Insight's exclusive summary of clinical trial results that have been announced or published in the past...  &#

The Investment Case For Selecta Biosciences

Thursday 20th September 2018

Scythian Biosciences Closes Acquisition of MMJ International Investments Inc.

Closing of Argentine Acquisition is Key Benchmark in Finalization of Previously Announced $193 Million Sale of Assets in Latin America, Which as of Prior Day Close was Valued At Approximately $313 Million Scythian Appoints Andy DeFrancesco as Chairman TORONTO, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (Frankfurt: 9SB) (OTC – ...

Arcus Biosciences Announces Participation at Leerink Partners Roundtable Series: Rare Disease & Oncology

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced Terry Rosen, Ph.D., Chief Executive Officer, and Jennifer Jarrett, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Dis...

Quadrant Biosciences secures NIH grant for novel autism spectrum disorder diagnostic assay

This collaborative award follows the company’s successful Phase I findings and will support the ongoing work of investigators Frank Middleton, PhD. at SUNY Upstate Medical University, Steven Hicks, The post Quadrant Biosciences secures NIH grant for novel autism spectrum disorder diagnostic assay appeared first on Compelo Medical Devices.

Predicine and Flagship Biosciences Partner to Support Global Biomarker Development

Predicine and Flagship Biosciences are excited to announce a strategic venture to provide complimentary and comprehensive biomarker profiling to empower clinical trials in the immuno-oncology (IO) space. HAYWARD, Calif. and WESTMINSTER, Colo. (PRWEB) September 20, 2018 Predicine and Flagship Biosciences are excited to announce a strategic venture. The synergistic combination of Predicine’s Gene...

ACEA Biosciences Releases New Version of NovoExpress® Flow Cytometry Software.

ACEA Biosciences releases a new version of NovoExpress® Flow Cytometry software, which provides simplified, automated, and integrated Flow Cytometry data collection & analysis solutions to Flow users of all experience levels. SAN DIEGO (PRWEB) September 20, 2018 We are excited to announce the release of the new 1.3.0 version of NovoExpress® software which supports the recently lau...

Pressure BioSciences' ultra-high pressure products featured in Chicago food tech conference

The company's products would be useful against dangerous bacteria like E. coli or salmonella

Wednesday 19th September 2018

Selecta Biosciences to Present at the Jefferies Gene Therapy Summit on September 27, 2018

WATERTOWN, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that CSO Takashi Kei Kishimoto, Ph.D., will present at the Jefferies Gene Therapy Summit in New York City at 9:10 a.m. ET on Thursday, Septe...

Taconic Biosciences Becomes the First Animal Model Provider on Federal General Services Administration

RENSSELAER, N.Y., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces a new relationship with Government Scientific Source (GSS). GSS is a leading dedicated distributor of laboratory products and equipment to federal, state, and local governments.  Most notably, GSS has direct procurement relationships ...

UPDATE— Taconic Biosciences Becomes the First Animal Model Provider on General Services Administration Contract Schedule

RENSSELAER, N.Y., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces a new relationship with Government Scientific Source (GSS). GSS is a leading dedicated distributor of laboratory equipment to federal, state, and local governments on contract with the GSA (General Services Administration).  By having...

FDA Grants Rare Pediatric Disease Designation to Cellectar’s Investigational Treatment for Osteosarcoma

MADISON, Wis., Sept. 17, 2018 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to CLR 131 for the treatment of …

Cerebrum Therapeutics Wins Biotech Startup Pitch Competition Co-Sponsored by Scientist.com and iPEPS-ICM

France-based company takes top honors in startup competition for early stage biotechs accelerating CNS disease research Scientist.com, the life science industry’s leading online marketplace for outsourced research, and the Brain and Spine Institute incubator, iPEPS-ICM, the first innovation accelerator dedicated to brain diseases in

Quadrant Biosciences Awarded $2 Million NIH Grant for Novel Autism Spectrum Disorder Diagnostic Assay

NIH Small Business Technology Transfer grant to support “game-changing” epigenetic ASD diagnostic test Quadrant Biosciences Inc., a developer of novel diagnostic technologies, has been awarded a $2 million Phase II Small Business Technology Transfer (STTR) grant from the National Institutes of Health (NIH) for the refinement and commercialization o...

Profectus BioSciences Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09052018] Prices from USD $250

SummaryProfectus BioSciences Inc Profectus is a clinicalstage vaccine development company that designs and develops preventive and therapeutic vaccines for infectious diseases and oncolytic vaccines for cancer immunotherapy. The company's products include genevax therapeutic vaccines, vesiculovax prophylactic vaccines and additional prophylactic vaccines. It uses PBS Vax technology platform for th...

Tuesday 18th September 2018

Precision BioSciences and Gilead partner in hep B drug development deal

Gilead Sciences Inc. and Precision BioSciences Inc. penned an agreement to discover and develop new treatments for hepatitis ...

Arix Biosciences’ investee company Iterum kicks off phase III trials of next-generation antibiotic

Unlike most penem drugs, Iterum’s sulopenem can be taken orally, which is why analysts think it has the potential to become a blockbuster antibiotic drug

We’re excited to announce the two promising #neuroscience startups that have been awarded the Pfizer-sponsored @LabCentral “Golden Tickets” - Tevard Biosciences and @QurAlisCo. Read more: https://on.pfizer.com/2MIawZe pic.twitter.com/8qpvYKWcqI

We’re excited to announce the two promising #neuroscience startups that have been awarded the Pfizer-sponsored @LabCentral “Golden Tickets” - Tevard Biosciences and @QurAlisCo. Read more: https://on.pfizer.com/2MIawZe  pic.twitter.com/8qpvYKWcqI

Aspect Biosystems Announces Liver Tissue Collaboration with JSR

Aspect Biosystems, a privately held biotechnology company focused on commercializing cutting-edge bioprinting technologies, is pleased to announce a new collaboration to develop human liver tissue with

Harpoon Therapeutics Announces Appointments to Board of Directors and Management Team

Jonathan Drachman, M.D., former CMO of Seattle Genetics, Brings Immuno-Oncology Expertise to Board Harpoon Therapeutics, Inc., a clinical-stage immuno-oncology company developing a new class of T cell engaging therapeutics, announced today that it has appointed Jonathan Drachman, M.D., to its Board of Directors and Mr. Chris Whitmore to Vice President,...

AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-PA01 Targeting Pseudomonas Aeruginosa Infections

The FDA is in general agreement with the design of two proposed randomized clinical trials of AB-PA01, hospital-acquired and ventilator-associated pneumonia (HAP/VAP) due to P. aeruginosa and for P. aeruginosa bacteremia, and no additional preclinical or clinical data are required to proceed with both trials Based on the pos...

Cellectar's osteosarcoma drug granted rare pediatric disease status

The FDA granted rare pediatric disease status to Cellectar Biosciences' CLR 131, being developed to treat patients with osteo -More- 


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks